Arlington, VA– The Bio-Process Systems Alliance (BPSA), the international association for the single-use bioprocessing industry, has announced its newly elected Board members for 2025–2026, following the December 5th Board meeting.

Mark Petrich, PhD, Vice President, Process Development & Validation, Krystal Biotech, Inc., was re-elected as Chair for a second two-year term, and Todd Kapp, CEO of Business Development at Wautoma Biotech LLC, was re-elected as First Vice Chair.

Brendan Lucey, Cross Business Unit Director of Marketing Strategy-Life Sciences, Entegris, Inc., and Ping Wang, PhD, Director, Material Sciences, Therapeutics Development & Supply (TDS), Discovery, Product Development & Supply, Johnson & Johnson Innovative Medicine, were elected to two-year terms as Directors at-large.

Lucey oversees the go-to-market strategy for Life Sciences at Entegris. He has previously served on the BPSA Board and currently chairs the BPSA Cell and Gene Therapy Committee. A biologist by training, he previously held positions at CDMOd, Lonza, Sartorius, ILC Dover and Gemini Bio.

Wang serves as a Scientific Director at Johnson & Johnson Innovative Medicine, responsible for the selection, qualification and investigation of single-use materials used for the J&J large molecules R&D and manufacturing network. Within BPSA, Ping is actively engaged in the BPSA Cell & Gene Therapy, End-user Committee and X-ray Sterilization Committees. Ping earned a PhD from the College of Pharmacy at University of Georgia, an MBA from Drexel University, and MS and BS degrees from Peking University.

Patrick Evrard, Quality Assurance/Regulatory Affairs, Cytiva; Charlott Masy, PhD, Senior Manager, GSK; Ralph Daumke, Market Manager EMEA, PendoTECH; Hernán Parma, Head of Sales-America, RENOLIT Healthcare and Stuart Tindal, EngD., PhD, Product Manager, Sartorius, were also re-elected as Directors-at-Large for two-year (2025-2026) terms.

“I extend my congratulations to Mark and Todd on their re-election as Chair and First Vice Chair,” said BPSA Executive Director Chris Clark. “As BPSA enters its 20th year, their extensive experience and leadership will be critical in guiding the Alliance as we move forward. I also congratulate our new and returning Board members and thank all our dedicated volunteer leaders for their time, expertise, and commitment to advancing BPSA’s mission.” Clark added, “A special thanks to Matt Sitcoske of High Purity New England and Danielle Arcuri of Qosina Corporation for their invaluable contributions as Directors-at-Large as their terms conclude this year.”

BPSA Executive Board Officers:

  • Chair: Mark Petrich, PhD, Krystal Biotech
  • 1st Vice Chair: Todd Kapp, Wautoma Biotech, LLC
  • 2nd Vice Chair: Kirsten Strahlendorf, Sanofi
  • Secretary: Todd Andrews, CPC
  • Treasurer: Ravi Narayanan, Dupont

At-Large Directors (newly elected) through 2026:

  • Brendan Lucey, Entegris
  • Ping Wang, PhD, Johnson & Johnson

At-Large Directors continuing through 2025 and/or 2026: 

  • Monica Cardona, Millipore Sigma
  • Brian Chung, Syensqo
  • Ralph Daumke, PendoTECH
  • Patrick Evrard, Cytiva
  • Jayanthi Grebin, Freudenberg Medical
  • Dianne Heiler, Repligen Corporation
  • Charlotte Masy, PhD, GSK
  • Hernán Parma, RENOLIT Healthcare
  • John Puglia, PhD, Thermo Fisher Scientific
  • Stuart Tindal, EngD, PhD, Sartorius
  • Thomas Vandromme, Meissner
  • Chris Wilkins, PhD, Filtration Group

Board members are elected by BPSA’s general membership to serve staggered two-year terms. They establish governing policies, determine budget priorities, and set strategic goals to advance the organization and its mission of supporting the single-use bioprocessing industry globally.

Please visit https://bpsalliance.org/about/board-of-directors/ for a complete list of BPSA Board of Directors.

About BPSA

An affiliate of SOCMA, the Bio-Process Systems Alliance, is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, development of consensus guides and networking opportunities among its member companies. For more information, visit www.bpsalliance.org.

ARLINGTON, VA – The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, announced it expanded its Board of Directors to 19 members to lead the organization in 2024/2025 during its recent election.

Kirsten Strahlendorf, M.Eng., P.Eng., PMP, Senior Unit Head, BioProcess Engineering Unit, Sanofi, has been elected Second Vice Chair; Todd Andrews, Director Application and Business Development, Biopharma, CPC, has been re-elected Secretary, and Ravi Narayanan, Global Product Management Leadership-Biopharma & Medical Device, Nordson Medical has been re-elected Treasurer. Also, Chris Wilkins, PhD, Vice President, Strategic Marketing, Filtration Group; Jayanthi Grebin, Business Development Manager Pharmaceuticals NA, Freudenberg Medical; Thomas Vandromme, Business Development Director, Meissner; Monica Cardona, Global Senior Marketing Manager Single Use Systems, Millipore Sigma; Dianne Heiler, Global Head of Packaging Engineering and Sustainability, Repligen Corporation; Brian Chung, Senior Key Account Manager, Specialty Polymers, Solvay and John Puglia, PhD, Senior Director, Global R&D, Thermo Fisher Scientific were elected as Directors-at-Large.

“Congratulations to Kirsten, Todd and Ravi on being elected to the BPSA Executive Board and congratulations to our new and returning BPSA Board members,” said Mark Petrich of Krystal Biotech, BPSA Chair. “I want to thank each of our dedicated volunteer leaders who have chosen to contribute their time and expertise to the BPSA Board. I look forward to working together to advance the mission of BPSA. I would like to express my appreciation to Dan Rosen, Vice President & General Manager, Thermo Fisher Scientific and Scott Patterson, Vice President Pharma & Biotech Technical Support, ILC Dover, whose terms as Directors-at-Large are ending this year.”

BPSA Executive Board Officers:

  • Chair: Mark Petrich, PhD, Krystal Biotech
  • 1st Vice Chair: Todd Kapp, Entegris, Inc.
  • 2nd Vice Chair: Kirsten Strahlendorf, Sanofi
  • Secretary: Todd Andrews, CPC
  • Treasurer: Ravi Narayanan, Nordson Medical

At-Large Directors (newly elected) through 2025:

  • Chris Wilkins, PhD, Filtration Group
  • Jayanthi Grebin, Freudenberg Medical
  • Thomas Vandromme, Meissner
  • Dianne Heiler, Repligen Corporation
  • John Puglia, PhD, Thermo Fisher Scientific  

At-Large Directors continuing through 2024/2025:

  • Patrick Evrard, Cytiva
  • Charlotte Masy, GSK
  • Mark Sitcoske, High Purity New England
  • Monica Cardona, Millipore Sigma
  • Ralph Daumke, PendoTECH
  • Danielle Arcuri, Qosina Corporation
  • Hernán Parma, RENOLIT Healthcare
  • Elisabeth Vachette, Sartorius
  • Brian Chung, Solvay

Board members are elected by the general membership and serve staggered two-year terms. The Board determines the governing policies of BPSA, establishes the budget and priorities, and directs the organization’s goals and priority areas of focus.

Please visit https://bpsalliance.org/about/board-of-directors/ for a complete list of BPSA Board of Directors.

The Bio-Process Systems Alliance (BPSA), is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, development of consensus guides and networking opportunities among its member companies. For more information, visit www.bpsalliance.org, or contact Executive Director Chris Clark at cclark@socma.org.

Arlington, VA – The Bio-Process Systems Alliance (BPSA) has submitted comments in response to the European Chemical Agency’s (ECHA) proposed ban on per- and poly-fluoroalkyl substances (PFAS).

In February, ECHA announced its proposed restriction on PFASs, a unique family of nearly 10,000 substances, including fluoropolymers, under the European Union’s Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation which addresses the production and use of certain chemical substances, and their potential impacts on human health and the environment. PFAS are used extensively across multiple industries, including bioprocessing, due to their unique functional properties and low reactivity.

This restriction proposes a universal ban over time on the use of all fluoropolymers in all applications, without distinguishing between fluoropolymers and other PFAS substances. Fluoropolymers, including PTFE and PVDF, are some of the most common PFAS types understood to be used in the bioprocess industry, considered as polymers of low concern by the Organisation for Economic Co-operation and Development, and deemed to have insignificant environmental and human health impacts. In its response to ECHA, BPSA requested that pharmaceutical and biopharmaceutical processing, including its supporting supply chain, be regarded as a sector, and permitted the same exemption, or unlimited derogation, as medicinal products.

“BPSA maintains a commitment to sustainability and fully supports efforts to minimize and mitigate the presence of substances which pose a threat to human health and the environment. However, the proposed broad restriction of PFAS covering fluoropolymers would have unintended consequences on the global manufacturing of biopharmaceutical products ultimately impacting availability of existing medicinal therapies, including vaccines, as well as the development of new therapies,” said BPSA Executive Director, Chris Clark. “Let’s find solutions that better balance the environmental and health concerns with the needs of patients, consumers and the bioprocessing industry.”

BPSA is committed to working collaboratively to ensure any proposed restrictions consider the unique challenges of the bioprocessing industry and the needs of patients and consumers. We urge ECHA to reconsider its proposed restriction based on the available scientific data and risk assessments regarding PFAS substances, including fluoropolymers, used in bioprocessing.

BPSA also supports the positions of the European Federation of Pharmaceutical Industries and Associations, BioPhorum, the European Sealing Association, the American Chemistry Council, and the American Society of Mechanical Engineers – Biopharmaceutical Process Equipment sector.

The Bio-Process Systems Alliance (BPSA) was formed in 2005 as an industry-led international industry association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. www.bpsalliance.org.

July 12, 2023 – Arlington, VA – The Bio-Process Systems Alliance (BPSA) announces the release of its latest guide, “X-Ray Sterilization of Single-Use Bioprocessing Equipment, Part 2: Representative Qualification Data, which serves to follow up on BPSA’s 2021 white paper, “X-Ray Sterilization of Single-Use Bioprocess Equipment, Part 1: Industry Need, Requirements & Risk Evaluation.”

Supply challenges and availability of gamma irradiation for sterilization have continued to increase, leading many single-use component and system suppliers to implement X-ray irradiation as an alternative to gamma irradiation. To support the risk assessments needed for such implementation, BPSA has generated supporting data evaluating the performance levels of X-ray sterilization and gamma-ray sterilization on certain single-use materials.

“There is a lot of concern about whether gamma contract irradiation capacity will be sufficient to meet the increasing demand from the bioprocessing industry,” said James Hathcock of Cytiva, Co-Chair of the BPSA X-ray Committee. “This research and accompanying white paper is a critical initiative for BPSA and the entire single-use industry.”

The resulting data in the new BPSA guide demonstrates the equivalent impact of X-ray irradiation of single-use materials as gamma. It also includes examples of data comparing X-ray and gamma irradiated components, generated by multiple component manufacturers for different types of single-use components and materials. “We are very pleased the examples verify the science-based understanding that X-ray and gamma impacts on single-use systems are equivalent,” said Samuel Dorey of Sartorius, BPSA X-ray Committee Co-Chair.

“I want to thank the BPSA X-ray Committee and its Co-Chairs, James Hathcock of Cytiva and Samuel Dorey of Sartorius, for their leadership of this initiative,” said BPSA Chair Mark Petrich, PhD, Krystal Biotech. “The results presented in this white paper are very good news, not only for single-use suppliers, but for customers and patients around the world who rely on our products. Advancing X-ray as a mode of sterilization is critical, for BPSA members and the broader bioprocessing industry.”

The 63-page guide results from a multi-year project, produced by BPSA members, industry stakeholders and subject-matter experts. The project team met with FDA’s Center for Drug Evaluation & Research Emerging Technologies Team, the European Medicines Agency Quality Innovation Group, and the Japan Pharmaceuticals and Medical Devices Agency to advance the adoption of X-ray technology for sterilization.

Please contact BPSA Executive Director, Chris Clark, at cclark@socma.org, and/or visit the BPSA website to download a copy of the white paper.

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliate of SOCMA, was formed in 2005 as an industry-led international industry association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. www.bpsalliance.org.

May 2, 2023 – ARLINGTON, VA – The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, announced the election of a Treasurer to its Executive Board and one Director-At-Large to its Board of Directors. Mr. Ravi Narayanan, Global Product & Market Management, Nordson Medical (Ft. Collins, CO) has been elected as BPSA Treasurer, succeeding Mr. Eric Isberg, who vacated the role last year. In addition, Mr. Scott Patterson, Vice President, PharmBio Technical Support, ILC Dover (Frederica DE) has been elected as Director-At-Large.

“The Alliance is pleased to welcome Ravi to the Executive Board as Treasurer and to welcome Scott to the Board as Director-At-Large,” said BPSA Chairman Mark Petrich of Krystal Biotech. “Ravi has been very active in BPSA and has served on the Board of Directors since 2022. Scott has been an active contributor and has been involved in BPSA activities for a number of years. I look forward to working with each of them to advance the use of single-use technologies in biopharmaceutical and vaccine production and to promote the mission and objectives of BPSA.”

Ravi Narayanan has over twenty-five years of leadership experience in product management and strategic marketing, new product development, and program management in the biopharmaceutical and medical industries. Ravi joined the BPSA Board in 2022 and has served in leadership positions in several other industry organizations affiliated with medical and biopharma devices, and disposables.

Scott Patterson has been active in a range of processing technologies for over 40 years with the past 25 years emphasizing pharmaceutical and biopharmaceutical processing. As a Vice President and Technical Leader with ILC Dover, Scott has focused on the use of single-use systems applied for high containment when handling potent compounds or solving large molecule upstream processing challenges. Scott has participated in multiple industry advocacy organizations including two BPSA committees.

The complete roster of BPSA Board Members can be found here: https://bpsalliance.org/about/board-of-directors/

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliated organization of the Society of Chemical Manufacturers & Affiliates (SOCMA), was formed in 2005 as an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. Learn more at www.bpsalliance.org

December 19, 2022 – ARLINGTON, VA. – The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, is pleased to announce the election of the following BPSA Executive Board members and Directors-at-Large for 2023/2024. 

Mark Petrich, PhD, Vice President, Process Development and Validation, Krystal Biotech, Inc. has been elected BPSA Chair, 2023-2024; Joseph St. Laurent, Head of Industry Relations & Regulatory Expert, Solvias, Inc. has been elected First Vice Chair; Todd Kapp, Global Commercial Development Director-Life Sciences, Entegris, Inc., has been elected Second Vice Chair, and Hernan Parma of Renolit Healthcare and Danielle Arcuri of Qosina, Inc. have been elected to the Board as Directors-at-Large. 

“I want to congratulate Mark on being elected BPSA Chair” said BPSA outgoing Chair, Jeff Carter, PhD, of Cytiva, whose term as Chair is ending on December 31, 2022. “The BPSA Board represents the entire value chain of the single-use industry, inclusive of resin producers, component manufacturers, system integrators, global OEM suppliers, analytical laboratories and end-users, and we are pleased to have an end-user/pharmaceutical manufacturer in the role of BPSA Chair for the first time.”

“I also want to congratulate Joseph St. Laurent of Solvias, Inc. on being elected First Vice Chair, Todd Kapp of  Entegris, Inc., on being elected Second Vice Chair, and Hernan Parma of Renolit Healthcare and Danielle Arcuri of Qosina, Inc. on being elected to the Board,” Carter continued. “We thank each of our volunteer leaders for their desire to serve on the BPSA Board, and we look forward to working with them in continuing to advance the adoption and use of single-use manufacturing processes and systems in vaccine and biopharmaceutical production. We also want to thank Robert Sassa of W. L. Gore and Scott Herskovitz of Qosina, whose terms as Directors-at-Large are ending this year.” 

Mark has been active with BPSA for include over ten years, including Board and Executive Board service, first with Merck & Co., Inc., and now at Krystal Biotech, Inc. He has served as Chair of the BPSA End-User Committee, co-authored several BPSA white papers, and helped successfully launch the BPSA Sustainability Committee. 

“It’s an honor to be elected to serve as BPSA Chair for 2023-2024. I want to thank Jeff for his service to the board and his leadership as Chair,” said Petrich. “Under Jeff’s leadership, the Alliance continued to grow and to serve the needs of its members and the biopharmaceutical industry. Many of the changes and challenges presented by the COVID-19 pandemic were addressed by single-use technologies and the efforts of BPSA member companies. As demand for single-use bioprocessing systems increased, Jeff’s leadership was key to putting BPSA in a position to help our members and the patients we all serve. I look forward to working with all the BPSA members and our volunteer leaders, as well as our partners and allied organizations, to continue to advance BPSA and the single-use bioprocessing industry.”

The roster of 2023/2024 Board Members is as follows:

BPSA Executive Board Officers: 

  • Chair: Mark Petrich, Krystal Biotech, Inc.
  • First Vice-Chair: Joseph St. Laurent, Solvias, Inc. 
  • Second Vice Chair: Todd Kapp, Entegris, Inc.
  • Treasurer:  VACANT
  • Secretary: Todd Andrews, CPC
  • Scientific Advisory Board Chair, Technical Committee Chair: Kirsten Strahlendorf, Sanofi Pasteur

At-Large Directors (newly elected/re-elected) through 2024:

  • Danielle Arcuri, Qosina Corporation
  • Ralph Daumke, PendoTECH
  • Patrick Evrard, Pall Corporation
  • Charlotte Masy, GSK Vaccines
  • Ravi Narayanan, Nordson Medical
  • Hernan Parma, Renolit Healthcare
  • Mark Sitcoske, High Purity New England
  • Elisabeth Vachette, Sartorius Stedim Biotech

At-Large Directors continuing through 2023:

  • Monica Cardona, MilliporeSigma
  • Brian Chung, Solvay, Inc.
  • Dan Rosen, Thermo Fisher Scientific

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliated organization of the Society of Chemical Manufacturers & Affiliates (SOCMA), was formed in 2005 as an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, sharing of best practices, development of consensus guides and business-to-business networking opportunities among its member company employees. For more information, visit www.bpsalliance.org, or contact Executive Director Chris Clark at cclark@socma.org.

ARLINGTON, Va., Oct. 4, 2022 /PRNewswire/ — The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, announced the election of a Secretary to its Executive Board and three at-large members to its Board of Directors for 2022-2023.

Todd Andrews, Director of Application & Business Development, Colder Products Company (CPC) will serve as Secretary, and new at-large members are:

  • Monica Cardona, Global Senior Program Manager, Single Use & Integrated Systems, MilliporeSigma
  • Brian Chung, Senior Key Account Manager – Specialty Polymers, Solvay
  • Dan Rosen, Vice President & General Manager – Single Use Technologies Flexible Solutions, Thermo Fisher Scientific

“The Alliance is pleased to have Todd Andrews join the Executive Board as Secretary,” said BPSA Chairman Jeff Carter of Cytiva. “He is very active in BPSA and has served on the Board of Directors for a number of years. I also welcome Monica Cardona, Dan Rosen and Brian Chung to the Board. I look forward to working with each of them to advance the use of single-use technologies in biopharmaceutical and vaccine production and advance the mission and objectives of BPSA.”

Todd has been involved in the single-use biopharmaceutical industry for more 15 years with a focus on single-use connection technology and has been an active BPSA member for almost 10 years. Todd has a bachelor’s degree in Plastics Engineering from University of Massachusetts, Lowell, and a master’s in business administration from the University of Saint Thomas.

Monica has been MilliporeSigma since 2019, and her previous roles include senior-level marketing and product management in the single-use and integrated systems sector. Monica served as Senior Marketing Manager-Single Use & Integrated Systems, and prior to her roles at MilliporeSigma, Monica was Global Product Manager Personal Protection Equipment with Cantel Medical Company and was Global Product Manager at Pall Life Sciences. Monica holds a bachelor’s degree in biology from Hofstra University and a master’s degree in biology from Adelphi University.

Prior to his role as Senior Account Manager at Solvay, Brian served as a Digital Sales Account Manager for Specialty Polymers and as Product Manager-Sulfation, Phosphation and Concentrates at Solvay. Brian holds a Bachelor of Science/M.S.E. in Chemical & Biomolecular Engineering from Johns Hopkins University.

Dan has been with Thermo Fisher Scientific for five years, and previously served as VP-GM for the company. Rosen has previous experience and expertise in investment banking and strategy consulting. Dan holds a bachelor’s degree from Brown University and a master’s in business administration from the Tuck School at Dartmouth College.

The complete roster of BPSA Board Members can be found here: https://bpsalliance.org/about/board-of-directors/

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliated organization of the Society of Chemical Manufacturers & Affiliates (SOCMA), was formed in 2005 as an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. Learn more at www.bpsalliance.org

Arlington, VA – The Bio-Process Systems Alliance (BPSA) announced the publication of its latest guide, the 19-page Single-Use Technologies Enable Manufacturers to Meet Pivotal Challenges of Viral Vector Manufacturing.

Recent years have seen dramatic breakthroughs in cell and gene therapies. Cell and gene therapy (CGT) is a science that is ushering in a new era in medicine. One of the main focuses of this technique is the optimization and delivery of Viral Vector vehicles that are mostly nanostructures, or viruses.

This new BPSA guide discusses present and future challenges in gene therapy manufacturing and how single-use technologies (SUTs) can improve the manufacturing process, including upstream production and downstream purification; product and operator safety; processing in closed systems and how single-use technology enables cost-effective manufacturing. The white paper also sheds light on some of the future opportunities for SUTs in gene therapy production.

“SUT’s are essential to viral vector manufacturing success, and this guide provides insights that will enable biopharmaceutical manufacturers to make smart choices about where single use can improve outcomes and speed of therapies to market,” said Brendan Lucey, Global Director of Cross Business Unit Market Strategy, Entegris, and Chair of the BPSA Cell and Gene Therapy Committee.

Viral Vector manufacturing is still in an early stage of development, and this emerging segment in biopharmaceutical manufacturing is benefiting from the recent surge in production of vaccines and monoclonal antibodies in response to the Covid-19 pandemic. While challenges still exist in the scale-up of Viral Vector manufacturing components, SUTs have been almost fully integrated in the process at commercial scale, and the SUT supply base is actively responding to these needs.

“The Viral Vector white paper is the culmination of an 18-month process, and I want to thank the BPSA Cell and Gene Therapy Committee, and all of the authors, contributors and editors for their hard work on this guide,” said Chris Clark, BPSA Executive Director. “BPSA and the single-use supply chain continues to work collaboratively to ensure a robust, safe, and reliable manufacturing base for cell and gene therapy production.”

Contact BPSA Executive Director, Chris Clark, to learn more, or visit the BPSA website to download a copy.


About BPSA
The Bio-Process Systems Alliance (BPSA), an affiliate of SOCMA, was formed in 2005 as an industry-led international industry association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. www.bpsalliance.org.

June 14, 2022 – Arlington, VA.–The Bio-Process Systems Alliance (BPSA), an affiliate of the Society of Chemical Manufacturers & Affiliates (SOCMA), announced it has named Christopher Clark, CAE, as its new Executive Director, effective June 1. Clark succeeds Kevin Ott, who served as BPSA Executive Director from 2007-2022.

“I want to congratulate and thank Kevin Ott for his 15 years of leadership and dedication to BPSA as Executive Director. Kevin has been with BPSA since the Alliance’s formation, and the organization would not be where it is today without his strategic guidance,” said BPSA Board Chair Jeff Carter, PhD, Consumables Product Strategy Leader, Cytiva.

Clark has spent more than 16 years in senior roles with national trade associations. As Executive Director, Clark will assume all day-to-day responsibilities of BPSA and work closely with the board of directors, membership, and affiliate partner the Society of Chemical Manufacturers & Affiliates (SOCMA), to ensure continued growth of the organization.

“The leadership and accomplishments Chris brings in association management make him an ideal choice for BPSA’s new Executive Director,” said Carter. “He brings significant leadership experience advocating for members and developing association programs and I look forward to working with him as we begin
the next chapter of our organization.”

Clark joins BPSA most recently from the North American Millers’ Association, where he served as Vice President, Communications & Administration. Prior to that, he was Vice President of Operations at the American Bakers’ Association, and Vice President of Operations, Member Service & Education at the
Snack Food Association (SNAC International). Clark is a Certified Association Executive (CAE) and member of the American Society of Association Executives.

“I am honored to join BPSA as its new Executive Director,” said Clark. “Single-Use Technologies are transforming how bio-pharmaceutical companies produce and deliver vaccines and other vital products, and I look forward to working with the BPSA membership and staff to advance the single-use
biopharmaceutical manufacturing industry,” said Clark.

About BPSA
Formed in 2005, the Bio-Process Systems Alliance (BPSA) is an industry-led international industry association of nearly 70 member companies dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA’s mission is to facilitate, globally, the development and manufacturing of biopharmaceuticals through the implementation of robust, safe and sustainable Single-Use Technologies.
www.bpsalliance.org

Contact
Chris Clark cclark@socma.org 571-348-5109

ARLINGTON, Va., Nov. 2, 2021 /PRNewswire/ — The Bio-Process Systems Alliance (BPSA), the international industry association of the single-use bio-processing industry, is pleased to announce the election of Board of Directors members who will serve two-year terms in leadership roles through December 31, 2023.

“With this election cycle we’re pleased to welcome back three members of our leadership team for new terms, as well as two re-elected at-large Directors, and two new Directors,” said Kevin Ott, BPSA Executive Director.

“As a unified Board, they represent a highly diverse leadership team that continues to work on issues of importance to the entire value chain of the single-use bio-processing industry, including resin suppliers, component manufacturers, systems integrators, auxiliary service and equipment suppliers and users,” Ott said. “This diversity is the historic strength of BPSA, and that tradition continues with our 2022/2023 slate of Board members.”

Executive Board officers for 2022-2023 are:

  • BPSA Treasurer: Eric Isberg, Savillex
  • Corporate Secretary: Janmeet Anant, Millipore Sigma
  • Scientific Advisory Board Chair: Kirsten Strahlendorf, Sanofi Pasteur Board of Directors members for 2022-2023 are:
  • Mukta Acharya, Thermo Fisher Scientific
  • Anna Maria Bertasa, Solvay Specialty Polymers
  • Todd Kapp, Entegris, Inc.
  • David Radspinner, ILC Dover

Continuing roles on the Executive Board through 2022 are:

  • Chair: Jeff Carter, Cytiva
  • First Vice-Chair: Mark Petrich, Krystal Biotech
  • Second Vice-Chair: Joseph St. Laurent, Chemic Laboratories, Inc.

Board of Directors members continuing through 2022 are:

  • Todd Andrews, CPC
  • Ralph Daumke, FILTROX AG
  • Patrick Evrard, Pall Corporation
  • Scott Herskovitz, Qosina Corporation
  • Charlotte Masy, GSK Vaccines
  • Ravi Narayanan, Nordson Medical
  • Robert Sassa, W.L. Gore & Associates
  • Mark Sitcoske, High Purity New England
  • Elisabeth Vachette, Sartorius Stedim Biotech

Both the Board and Executive Board hold bi-monthly virtual meetings. BPSA currently has 68 corporate members and is the primary trade association for the single-use industry. Headquartered in Washington, DC, BPSA has represented the full value-chain of single-use interests since 2005.

About BPSA

The Bio-Process Systems Alliance (BPSA), an affiliated organization of the Society of Chemical Manufacturers & Affiliates (SOCMA), was formed in 2005 as an industry-led corporate member industry association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, sharing of best practices, development of consensus guides and business-to-business networking opportunities among its member company employees. For more information, visit www.bpsalliance.org, or contact Executive Director Kevin Ott at kott@socma.org.

CONTACT: Kevin Ott, Executive Director, BPSA, (571) 348-5104, kott@socma.org